U.S. Markets close in 59 mins
| Symbol | Value | Change | Percentage Change |
|---|---|---|---|
| DJIA | 11,414.82 | -217.56 | -1.87% |
| NASDAQ | 2,296.49 | -29.39 | -1.26% |
| S&P 500 | 1,260.25 | -21.94 | -1.71% |
| Day Low 11:28 AM EDT | 31.25 | |
|---|---|---|
| Day High 09:31 AM EDT | 33.41 |
|
| Range | 2.16 | |
| Volume | 8.41 M | |
| 30-Day Avg. Vol. | 7.75 M |
|
| Difference | 8.40% | |
| Market Cap. | 15.31 B | |
| Change | -583.06 M | |
| Shares Out. | 471.6 M | |
| Percent Traded | 1.77% | |
| Revenue | 516.4 M | |
| Earnings | -665.9 M | |
| EPS (TTM) | -10.33997 |
| 52-Wk Low 7/30/07 | 16.37 | |
|---|---|---|
| 52-Wk High 7/10/08 | 37.45 |
|
| Range | 21.08 | |
| Prev. Close 7/23/08 | 33.54 | |
| Today's Open | 33.12 | |
| Change | -1.25% | |
| Dividend (TTM) | 0.00 | |
| Div. Yield (TTM) | 0.00% |
|
| Beta | 0.9053 | |
| P/E Ratio (TTM) | — | |
| P/E Ratio (Fwd.) | -66.00 |
Elan has brains on its mind. The company is focused on the development of pharmaceuticals for neurological and autoimmune diseases, as well as for severe pain and infectious diseases. Its product offerings ... View Full Description
| Earnings/Share(EPS) | Estimate | Actual | Difference |
|---|---|---|---|
| 2 Quarters Ago | -0.145 12/31/07 | -0.18 12/31/07 |
-0.035
Missed
|
| Last Quarter | -0.15 3/31/08 | -0.18 3/31/08 |
-0.03
Missed
|
| Quarterly - 12/31/2002 | Annual - 2007 | |
|---|---|---|
| Total Revenue | 237.96 M | 516.40 M |
| Gross Profit | 116.11 M | 212.20 M |
| Operating Income | -531.16 M | -232.90 M |
| Net Income | -680.05 M | -665.90 M |
Real-Time Quote
